Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...

Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, ...

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who ...

A new study questioned the clinical utility of an algorithm meant to predict opioid use disorder (OUD) risk based on 15 ...

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...